Incidence and Survival of HNSCC Patients Living with HIV Compared with HIV-negative HNSCC Patients

Overview

Journal Eur Arch Otorhinolaryngol

Specialty Otorhinolaryngology

Date 2021 Jan 25

PMID 33492419

Citations 6

Authors

Katharina Haase

Iris Piwonski

Carmen Stromberger

Nadine Thieme

Max Heiland

Benedicta Beck-Broichsitter

Veit M Hofmann

Grzegorz Kofla

Steffen Sander

Ullrich Keilholz

Konrad Neumann

Katharina Stolzel

Heidi Olze

Philipp Arens

Steffen Dommerich

Annekatrin Coordes

Affiliations

Soon will be listed here.

Abstract

Purpose: The aim was to analyze the incidence and survival of patients living with HIV (PLWH) with head and neck squamous cell carcinoma (HNSCC) and to compare with a control group of HIV-negative HNSCC patients.

Methods: Clinicopathological data and predictors for overall survival (OS) and disease-free survival (DFS) were investigated (2009-2019).

Results: 50 of 5151 HNSCC patients (0.97%) were PLWH, and 76% were smokers. Age ≤ 60 years, HIV-PCR ≤ 50 copies, CD4 cells ≤ 200/mm, cART treatment, T and UICC classification, oral cavity and nasal/paranasal sinuses, and therapy were significantly associated with OS in univariate analysis. In the multivariate analysis, only age and HIV-PCR independently predicted OS. The OS of the 50 PLWH was not significantly altered compared with the 5101 HIV-negative controls. However, OS and DFS were significantly inferior in advanced tumor stages of PLWH compared with an age-matched control group of 150 HIV-negative patients.

Conclusions: PLWH were diagnosed with HNSCC at a significantly younger age compared to HIV-negative patients. Taking into account patient age at initial diagnosis, both OS and DFS rates in PLWH are significantly worse compared with a matched control group of HIV-negative patients in advanced tumor stages UICC III/IV. The prognosis (OS) is improved when taking cART treatment, the HIV viral load is undetectable and CD4 count is high.

Citing Articles

Construction of a prognosis model of head and neck squamous cell carcinoma pyroptosis and an analysis of immuno-phenotyping based on bioinformatics.

Pan W, Huang W, Zheng J, Meng Z, Pan X Transl Cancer Res. 2024; 13(1):299-316.

PMID: 38410218 PMC: 10894328. DOI: 10.21037/tcr-23-922.

A Random Forest Model for Post-Treatment Survival Prediction in Patients with Non-Squamous Cell Carcinoma of the Head and Neck.

Zhang X, Liu G, Peng X J Clin Med. 2023; 12(15).

PMID: 37568416 PMC: 10419643. DOI: 10.3390/jcm12155015.

Human Immunodeficiency Virus Is Associated With Poor Overall Survival Among Patients With Head and Neck Cancer.

Salahuddin S, Cohen O, Wu M, Perez Irizarry J, Vega T, Gan G Clin Infect Dis. 2022; 76(8):1449-1458.

PMID: 36520995 PMC: 10319962. DOI: 10.1093/cid/ciac924.

Oral infections in oral cancer survivors: A mini-review.

Pispero A, Lombardi N, Manfredi M, Varoni E, Sardella A, Lodi G Front Oral Health. 2022; 3:970074.

PMID: 36338574 PMC: 9634540. DOI: 10.3389/froh.2022.970074.

Impact of human immunodeficiency virus status on laryngeal cancer survival and locoregional control.

Weinreb S, Piersiala K, Dhar S, Hillel A, Akst L, Best S Laryngoscope Investig Otolaryngol. 2022; 7(1):153-160.

PMID: 35155793 PMC: 8823145. DOI: 10.1002/lio2.736.

References

Kreimer A, Clifford G, Boyle P, Franceschi S . Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomarkers Prev. 2005; 14(2):467-75. DOI: 10.1158/1055-9965.EPI-04-0551. View

Mourad W, Hu K, Ishihara D, Shourbaji R, Lin W, Kumar M . Tolerance and toxicity of primary radiation therapy in the management of seropositive HIV patients with squamous cell carcinoma of the head and neck. Laryngoscope. 2013; 123(5):1178-83. DOI: 10.1002/lary.23874. View

Singh B, Balwally A, Shaha A, Rosenfeld R, Har-El G, Lucente F . Upper aerodigestive tract squamous cell carcinoma. The human immunodeficiency virus connection. Arch Otolaryngol Head Neck Surg. 1996; 122(6):639-43. DOI: 10.1001/archotol.1996.01890180047012. View

Lassen P, Eriksen J, Krogdahl A, Hamilton Therkildsen M, Ulhoi B, Overgaard M . The influence of HPV-associated p16-expression on accelerated fractionated radiotherapy in head and neck cancer: evaluation of the randomised DAHANCA 6&7 trial. Radiother Oncol. 2011; 100(1):49-55. DOI: 10.1016/j.radonc.2011.02.010. View

Kamangar F, Dores G, Anderson W . Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol. 2006; 24(14):2137-50. DOI: 10.1200/JCO.2005.05.2308. View

Robbins H, Pfeiffer R, Shiels M, Li J, Hall H, Engels E . Excess cancers among HIV-infected people in the United States. J Natl Cancer Inst. 2015; 107(4). PMC: 4334816. DOI: 10.1093/jnci/dju503. View

Picard A, Arowas L, Piroth L, Heard I, Ferry T . Head and neck squamous cell carcinoma in people living with HIV in France. Med Mal Infect. 2018; 48(8):503-508. DOI: 10.1016/j.medmal.2018.05.002. View

Franceschi S, Dal Maso L, Rickenbach M, Polesel J, Hirschel B, Cavassini M . Kaposi sarcoma incidence in the Swiss HIV Cohort Study before and after highly active antiretroviral therapy. Br J Cancer. 2008; 99(5):800-4. PMC: 2528138. DOI: 10.1038/sj.bjc.6604520. View

Blot W, McLaughlin J, Winn D, Austin D, Greenberg R, Preston-Martin S . Smoking and drinking in relation to oral and pharyngeal cancer. Cancer Res. 1988; 48(11):3282-7. View

10.

Liu R, Zhang L, Yang J, Zhang X, Mikkelsen R, Song S . HIV Protease Inhibitors Sensitize Human Head and Neck Squamous Carcinoma Cells to Radiation by Activating Endoplasmic Reticulum Stress. PLoS One. 2015; 10(5):e0125928. PMC: 4416809. DOI: 10.1371/journal.pone.0125928. View

11.

Mourad W, Hu K, Shasha D, Concert C, Ishihara D, Lin W . Long-term outcome of seropositive HIV patients with head and neck squamous cell carcinoma treated with radiation therapy and chemotherapy. Anticancer Res. 2013; 33(12):5511-6. View

12.

Kirk G, Merlo C, O Driscoll P, Mehta S, Galai N, Vlahov D . HIV infection is associated with an increased risk for lung cancer, independent of smoking. Clin Infect Dis. 2007; 45(1):103-10. PMC: 4078722. DOI: 10.1086/518606. View

13.

Picard A, Badoual C, Hourseau M, Halimi C, Pere H, Dib F . Human papilloma virus prevalence in HIV patients with head and neck squamous cell carcinoma. AIDS. 2016; 30(8):1257-66. DOI: 10.1097/QAD.0000000000001030. View

14.

Gleber-Netto F, Zhao M, Trivedi S, Wang J, Jasser S, McDowell C . Distinct pattern of TP53 mutations in human immunodeficiency virus-related head and neck squamous cell carcinoma. Cancer. 2017; 124(1):84-94. PMC: 5785080. DOI: 10.1002/cncr.31063. View

15.

Shibuya T, Nugyen N, McLaren C, Li K, Wei W, Kim S . Clinical significance of poor CD3 response in head and neck cancer. Clin Cancer Res. 2002; 8(3):745-51. View

16.

Anaya-Saavedra G, Flores-Moreno B, Garcia-Carranca A, Irigoyen-Camacho E, Guido-Jimenez M, Ramirez-Amador V . HPV oral lesions in HIV-infected patients: the impact of long-term HAART. J Oral Pathol Med. 2013; 42(6):443-9. DOI: 10.1111/jop.12032. View

17.

Gritz E, Vidrine D, Lazev A, Amick 3rd B, Arduino R . Smoking behavior in a low-income multiethnic HIV/AIDS population. Nicotine Tob Res. 2004; 6(1):71-7. DOI: 10.1080/14622200310001656885. View

18.

Brickman C, Palefsky J . Cancer in the HIV-Infected Host: Epidemiology and Pathogenesis in the Antiretroviral Era. Curr HIV/AIDS Rep. 2015; 12(4):388-96. DOI: 10.1007/s11904-015-0283-7. View

19.

Polesel J, Clifford G, Rickenbach M, Dal Maso L, Battegay M, Bouchardy C . Non-Hodgkin lymphoma incidence in the Swiss HIV Cohort Study before and after highly active antiretroviral therapy. AIDS. 2007; 22(2):301-6. DOI: 10.1097/QAD.0b013e3282f2705d. View

20.

Zhang H, Kim S, Chen Z, Nannapaneni S, Chen A, Moore C . Prognostic biomarkers in patients with human immunodeficiency virus-positive disease with head and neck squamous cell carcinoma. Head Neck. 2017; 39(12):2433-2443. PMC: 5808949. DOI: 10.1002/hed.24911. View